

Add the following new claim 12:

94 12. (new) A method for treating diabetes comprising administering to an individual in need of such treatment an effective amount of an analog according to claim 1 or 3.

Rewrite claims 4-6 and 8 to read as follows. A mark-up of the amended claims is submitted herein as Appendix A.

4. (amended) A peptide analogue as claimed in claim 1 or 3 wherein the substitution or modification is chosen from the group comprising D-amino acid substitutions in 1, 2 and/or 3 positions and/or N terminal glycation, alkylation, acetylation or acylation.

Q2 5. (amended) A peptide analogue as claimed in claim 1 or 3 wherein the amino acid in the 2 or 3 position is substituted by lysine, serine, 4-amino butyric, Aib, D-alanine, Sarcosine or Proline.

6. (amended) An analogue as claimed in claim 1 or 3 wherein the N terminus is modified by one of the group of modifications including glycation, alkylation, acetylation or by the addition of an isopropyl group.

Q3 8. (amended) A pharmaceutical composition including an analogue as claimed in claim 1 or 3.

Remarks

Claims 1-6 and 8-12 are pending in the application. The dependencies of certain claims have been reduced, to conform to United States practice. Claim 7 has been cancelled and presented as claim 12, in a method of treatment format consistent with United States practice. No new matter has been introduced.

An Abstract is submitted herewith, which is identical to the abstract appearing in the international application.

FINBARR PAUL MARY O'HARTE et al

A handwritten signature in black ink, appearing to read "Dan Monaco", is written over a horizontal line.

DANIEL A. MONACO

Registration No. 30,480

DRINKER BIDDLE & REATH LLP

One Logan Square

18th and Cherry Streets

Philadelphia, PA 19103-6996

Phone: (215) 988-3312

Fax: (215) 988-2757

Attorney for the Applicants

APPEENDIX A: Mark-up of amended claims

4. (amended) A peptide analogue as claimed in [any of the preceding claims] claim 1 or 3 wherein the substitution or modification is chosen from the group comprising D-amino acid substitutions in 1, 2 and/or 3 positions and/or N terminal glycation, alkylation, acetylation or acylation.

5. (amended) A peptide analogue as claimed in [any of the preceding claims] claim 1 or 3 wherein the amino acid in the 2 or 3 position is substituted by lysine, serine, 4-amino butyric, Aib, D-alanine, Sarcosine or Proline.

6. (amended) An analogue as claimed in [any of the preceding claims] claim 1 or 3 wherein the N terminus is modified by one of the group of modifications [include] including glycation, alkylation, acetylation or by the addition of an isopropyl group.

8. (amended) A pharmaceutical composition including an analogue as claimed in [any of the preceding claims] claim 1 or 3.

Abstract

Q) The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42, include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.
